Antibody-based immunotherapy of aciclovir resistant ocular herpes simplex virus infections

Bauer D, Keller J, Alt M, Schubert A, Aufderhorst UW, Palapys V, Kasper M, Heilingloh C, Dittmer U, Laffer B, Eis-Huebinger AM, Verjans GM, Heiligenhaus A, Roggendorf M, Krawczyk A (2017)


Publication Type: Journal article

Publication year: 2017

Journal

Book Volume: 512

Pages Range: 194-200

DOI: 10.1016/j.virol.2017.09.021

Abstract

The increasing incidence of aciclovir- (ACV) resistant strains in patients with ocular herpes simplex virus (HSV) infections is a major health problem in industrialized countries. In the present study, the humanized monoclonal antibody (mAb) hu2c targeting the HSV-1/2 glycoprotein B was examined for its efficacy towards ACV-resistant infections of the eye in the mouse model of acute retinal necrosis (ARN). BALB/c mice were infected by microinjection of an ACV-resistant clinical isolate into the anterior eye chamber to induce ARN and systemically treated with mAb hu2c at 24h prior (pre-exposure prophylaxis) or at 24, 40, and 56h after infection (post-exposure immunotherapy). Mock treated controls and ACV-treated mice showed pronounced retinal damage. Mice treated with mAb hu2c were almost completely protected from developing ARN. In conclusion, mAb hu2c may become a reliable therapeutic option for drug/ACV-resistant ocular HSV infections in humans in order to prevent blindness.

Authors with CRIS profile

Involved external institutions

How to cite

APA:

Bauer, D., Keller, J., Alt, M., Schubert, A., Aufderhorst, U.W., Palapys, V.,... Krawczyk, A. (2017). Antibody-based immunotherapy of aciclovir resistant ocular herpes simplex virus infections. Virology, 512, 194-200. https://doi.org/10.1016/j.virol.2017.09.021

MLA:

Bauer, Dirk, et al. "Antibody-based immunotherapy of aciclovir resistant ocular herpes simplex virus infections." Virology 512 (2017): 194-200.

BibTeX: Download